WEST LAFAYETTE, Ind., Oct. 12, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the publication of data showing that 72 percent of adenocarcinomas and 51 percent of squamous cell carcinomas of the lung were positive for the folate receptor (FR). Currently validated targeted therapies are effective in only a small minority of lung cancers so the FR may be an important molecular target for future lung cancer therapies. The data are published online in the journal Archives of Pathology & Laboratory Medicine.
